换一批Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction-Associated Steatotic Liver Disease.
第一作者：
Gabriele,Mocciaro
第一单位：
Roger Williams Institute of Liver Studies, Foundation for Liver Research, London, UK.
作者：
医学主题词
人类(Humans);男(雄)性(Male);女(雌)性(Female);中年人(Middle Aged);病例对照研究(Case-Control Studies);成年人(Adult);载脂蛋白CⅢ(Apolipoprotein C-III);氧化还原(Oxidation-Reduction);脂肪肝(Fatty Liver);串联质谱法(Tandem Mass Spectrometry);老年人(Aged);载脂蛋白E类(Apolipoproteins E);蛋白质组学(Proteomics);载脂蛋白类(Apolipoproteins);色谱法, 液相(Chromatography, Liquid);肝(Liver)
DOI
10.1111/liv.16200
PMID
39822152
发布时间
2026-06-27
基金项目
WT_/Wellcome Trust/United Kingdom
MR/S010483/1/MRC_/Medical Research Council/United Kingdom
Disease Model Core, Biochemistry Assay Lab, Histology Core and British Heart Foundation. M.F. is supported by the British Heart Foundation (FS/18/53/33863) and the British Heart Foundation Cambridge Centre for Research Excellence (RE/18/1/34212). This study was supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre. We would like to thank all participants in this study and the NIHR National BioResource. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. JLG is funded by the Medical Research Council (MR/S010483/1; MR/P011705/1; MR/P01836X/1; MR/X012700/1). F.G., F.R., R.K. and A.L.G. were funded by the Wellcome Trust (grants 106262/Z/14/Z, 106263/Z/14/Z), the MRC Metabolic Diseases Unit (grants MRC MC UU 12012/3, MRC MC UU12012/5) and by the NIHR Cambridge Biomedical Research Centre. The mass spectrometers were obtained using the Medical Research Council "Enhancing UK Clinical Research" grant (MR/M009041/1). The views expressed are those of the author(s) and not necessarily those of the relevant funding or supporting institutions. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript/ "National Centre for HPC, Big Data and Quantum Computing").A.V.P. is funded by MRC MDU, MRC Metabolic Diseases Unit (MC_UU_00014/5)/ H93C22000450007, Title PNNR/ CN00000013, CUP/ H93C22000430007, Title PNRR "National Center for Gene Therapy and Drugs based on RNA Technology", M4C2-Investment 1.4; Code/ CN00000041, CUP/ "ON Foods - Research and innovation network on food and nutrition Sustainability, Safety and Security - Working ON Foods"; Cod/ H93C22000630001, DD MUR 1550, Title/ "System Biology" approaches in HCV Patients with Residual Hepatic Steatosis after Viral Eradication; Cod PE00000003, CUP/ H53D23009960001, D.D. MUR 1366 (01-09-2023), Title/ P202222FCC, CUP/This research was supported by NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) funding to V.A., M.A., and M.V.The initial establishment of the cohorts was supported by the Evelyn Trust (funding to M.A. and A.V.P.), Mason Medical Research Trust (funding to V.A.), and the Academy of Medical Sciences (funding to V.A.). V.A. was supported by the University of Cambridge. M.A. is supported by Cambridge University Hospitals NHS Foundation Trust. M.V. is supported by the University of Bari (Horizon Europe Seed cod. id. S06-miRNASH), the Foundation for Liver Research (Intramural Funding), Associazione Italiana Ricerca sul Cancro (IG2022 Grant n. 27521) and Ministry of University and Research on Next Generation EU Funds [COD
- 浏览1
Liver international
e16200页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
